TW526063B - Pharmaceutical composition for use in removing bile salts - Google Patents
Pharmaceutical composition for use in removing bile salts Download PDFInfo
- Publication number
- TW526063B TW526063B TW087109749A TW87109749A TW526063B TW 526063 B TW526063 B TW 526063B TW 087109749 A TW087109749 A TW 087109749A TW 87109749 A TW87109749 A TW 87109749A TW 526063 B TW526063 B TW 526063B
- Authority
- TW
- Taiwan
- Prior art keywords
- cross
- linking agent
- patent application
- pharmaceutical composition
- scope
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract 11
- 239000003833 bile salt Substances 0.000 title abstract 2
- 229940093761 bile salts Drugs 0.000 title abstract 2
- 229920000642 polymer Polymers 0.000 claims abstract description 26
- 239000000178 monomer Substances 0.000 claims abstract description 17
- 239000003431 cross linking reagent Substances 0.000 claims description 23
- 238000011049 filling Methods 0.000 claims description 15
- BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 claims description 10
- 229920001519 homopolymer Polymers 0.000 claims description 3
- UYMKPFRHYYNDTL-UHFFFAOYSA-N ethenamine Chemical compound NC=C UYMKPFRHYYNDTL-UHFFFAOYSA-N 0.000 claims description 2
- ASVKKRLMJCWVQF-UHFFFAOYSA-N 3-buten-1-amine Chemical compound NCCC=C ASVKKRLMJCWVQF-UHFFFAOYSA-N 0.000 claims 1
- 229920002401 polyacrylamide Polymers 0.000 claims 1
- 150000001412 amines Chemical class 0.000 abstract description 14
- 229920006037 cross link polymer Polymers 0.000 abstract description 5
- 229920001577 copolymer Polymers 0.000 abstract description 3
- 150000003839 salts Chemical class 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 abstract 1
- 239000007787 solid Substances 0.000 description 36
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 34
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 27
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 25
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 20
- 239000000203 mixture Substances 0.000 description 18
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 235000012000 cholesterol Nutrition 0.000 description 15
- 229920000083 poly(allylamine) Polymers 0.000 description 13
- 238000003756 stirring Methods 0.000 description 13
- 239000000243 solution Substances 0.000 description 12
- 239000008280 blood Substances 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 11
- 238000004132 cross linking Methods 0.000 description 10
- 238000001914 filtration Methods 0.000 description 9
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 8
- 239000002775 capsule Substances 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 239000000047 product Substances 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 239000011575 calcium Substances 0.000 description 6
- 229910052791 calcium Inorganic materials 0.000 description 6
- 235000012054 meals Nutrition 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 4
- 201000005991 hyperphosphatemia Diseases 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- GVNWZKBFMFUVNX-UHFFFAOYSA-N Adipamide Chemical compound NC(=O)CCCCC(N)=O GVNWZKBFMFUVNX-UHFFFAOYSA-N 0.000 description 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 3
- MUXOBHXGJLMRAB-UHFFFAOYSA-N Dimethyl succinate Chemical compound COC(=O)CCC(=O)OC MUXOBHXGJLMRAB-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000000853 adhesive Substances 0.000 description 3
- 230000001070 adhesive effect Effects 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 235000021152 breakfast Nutrition 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 229910052698 phosphorus Inorganic materials 0.000 description 3
- 239000011574 phosphorus Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- KVNYFPKFSJIPBJ-UHFFFAOYSA-N 1,2-diethylbenzene Chemical compound CCC1=CC=CC=C1CC KVNYFPKFSJIPBJ-UHFFFAOYSA-N 0.000 description 2
- HPILSDOMLLYBQF-UHFFFAOYSA-N 2-[1-(oxiran-2-ylmethoxy)butoxymethyl]oxirane Chemical compound C1OC1COC(CCC)OCC1CO1 HPILSDOMLLYBQF-UHFFFAOYSA-N 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- VVJKKWFAADXIJK-UHFFFAOYSA-N Allylamine Chemical compound NCC=C VVJKKWFAADXIJK-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- 238000008214 LDL Cholesterol Methods 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- BYHHVXHXHCMLIG-UHFFFAOYSA-N ethenamine;ethene Chemical compound C=C.NC=C BYHHVXHXHCMLIG-UHFFFAOYSA-N 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- 238000001631 haemodialysis Methods 0.000 description 2
- 230000000322 hemodialysis Effects 0.000 description 2
- 238000010907 mechanical stirring Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000002694 phosphate binding agent Substances 0.000 description 2
- 229920000768 polyamine Polymers 0.000 description 2
- 239000001294 propane Substances 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 229940020428 renagel Drugs 0.000 description 2
- ZNSIZMQNQCNRBW-UHFFFAOYSA-N sevelamer Chemical compound NCC=C.ClCC1CO1 ZNSIZMQNQCNRBW-UHFFFAOYSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- KNKRKFALVUDBJE-UHFFFAOYSA-N 1,2-dichloropropane Chemical compound CC(Cl)CCl KNKRKFALVUDBJE-UHFFFAOYSA-N 0.000 description 1
- UWFRVQVNYNPBEF-UHFFFAOYSA-N 1-(2,4-dimethylphenyl)propan-1-one Chemical compound CCC(=O)C1=CC=C(C)C=C1C UWFRVQVNYNPBEF-UHFFFAOYSA-N 0.000 description 1
- OTIXUSNHAKOJBX-UHFFFAOYSA-N 1-(aziridin-1-yl)ethanone Chemical compound CC(=O)N1CC1 OTIXUSNHAKOJBX-UHFFFAOYSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- AOBIOSPNXBMOAT-UHFFFAOYSA-N 2-[2-(oxiran-2-ylmethoxy)ethoxymethyl]oxirane Chemical compound C1OC1COCCOCC1CO1 AOBIOSPNXBMOAT-UHFFFAOYSA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- IMROMDMJAWUWLK-UHFFFAOYSA-N Ethenol Chemical compound OC=C IMROMDMJAWUWLK-UHFFFAOYSA-N 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- 206010065973 Iron Overload Diseases 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 238000001793 Wilcoxon signed-rank test Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- RIDGBWXFVQBIOJ-UHFFFAOYSA-N azane propan-1-amine Chemical compound N.CCCN RIDGBWXFVQBIOJ-UHFFFAOYSA-N 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000011362 coarse particle Substances 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 239000000385 dialysis solution Substances 0.000 description 1
- 235000018823 dietary intake Nutrition 0.000 description 1
- GYZLOYUZLJXAJU-UHFFFAOYSA-N diglycidyl ether Chemical compound C1OC1COCC1CO1 GYZLOYUZLJXAJU-UHFFFAOYSA-N 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- ZQXSMRAEXCEDJD-UHFFFAOYSA-N n-ethenylformamide Chemical compound C=CNC=O ZQXSMRAEXCEDJD-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 238000001558 permutation test Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- XYFCBTPGUUZFHI-UHFFFAOYSA-O phosphonium Chemical compound [PH4+] XYFCBTPGUUZFHI-UHFFFAOYSA-O 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000010526 radical polymerization reaction Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 229940056345 tums Drugs 0.000 description 1
- 238000005292 vacuum distillation Methods 0.000 description 1
- 238000007738 vacuum evaporation Methods 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
Description
526063 A7 B7 五、發明説明()) 圖式簡單說明 圖示表示交聯聚烯丙胺在相對於基線L D L膽固醇之 L D L膽固醇的作用。 發明詳述 如前述,使用於本發明之聚合物包括,可選擇性地交 聯聚胺類其特徵係爲前述之化學式。較佳的聚合物爲聚烯 丙胺或聚乙烯胺◊重要地,該聚合物特徵可爲幾乎缺少在 單體,例如,係自胺聚合物之烷化獲得,之胺基基團上經 取代或爲取代之烷基取代基。即,該聚合物其特徵可爲該 聚合物幾乎無烷化胺單體。 該聚合物可爲同聚物或--個或多個包含胺單體或不包 含胺單體之共聚物。其中共聚物係由前述化學式之單體製 造,該共單體較佳爲情性,無毒性及/或具有膽酸隔離作 用性質。適合之不包含胺單體之實施例包括乙烯醇,丙烯 酸,丙烯醯胺,及乙烯甲醯胺。包含胺單體之實施例較佳 包括具有前述式1之單體。較佳地,該單體爲脂肪族。更 佳地,該聚合物爲同聚物,例如,同聚烯丙胺或同聚乙烯 胺。 較佳地,該聚合物係經由交聯成爲非水溶性。該交聯 劑其特徵可爲能與單體之胺基基團反應之官能基團。選擇 --------♦------IT------#1 (請先閱讀背面之注意事項再填寫本頁) 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) 526063 A7 B7 丨1__· .—*«·-·-··· -*——· -* -" . - '* " »^r—— - — . _ [| 五、發明説明(斗) 地,該交聯基團其特徵可爲雨個或多個與胺單體經過游離 基聚合作用之乙烯基。 c讀先閱讀背面之注意事項再填寫本贾) 適合之交聯劑之實施例包括丙烯醯氯,表氯醇( epichlorohydrin ) 丁二醇二縮水甘油醚( butanedioldiglycidyl ether),乙二醇二縮水甘油醚( ethanedioldiglycidyl ehter),及丁二酸二甲酯。 較佳之交聯劑爲表氯醇,因爲其高效果及低成本。表 氯醇亦爲有利的是因其低分子量及親水性本質,保持聚胺 膠體之水膨脹性。 交聯的等級使聚合物不溶且幾乎抗吸收及降解,藉以 限制聚合物對胃腸道的活性。因此,組成物在其活性內爲 非系統性的且將導致降低在患者中之副作用。典型地,該 交聯劑以基於單體加上交聯劑之總重量爲基礎,其量爲自 約0 · 5 — 2 5 % (更佳爲約2 · 5 — 2 0 %且最佳爲1 一 1◦%)之重量百分比存在。 典型地,該與胺聚合物反應之交聯劑的量爲足以引起 在約0 . 5及2 0%間之胺類與交聯劑反應0在一較佳之 具體實施例中,在約0 · 5及2 0 %間之胺類與交聯劑反 應。 本發明較佳之聚合物爲一般習知技藝已知。Holmes-Farley,等人(美國專利案號5,4 9 6,·5 4 5 )描述 脂肪胺聚合物於治療血磷酸鹽過多之用途。這些聚合物亦 被建議使用於治療鐵一超載(Mandeville等人,美國專 利案號5,4 8 7,8 8 8 ) ◊這兩件專利案所教示者倂 本紙張尺度適用中國國家標準(CNS ) A4規格(210X 297公釐) 526063 Α7 五、發明説明(7 ) 器,溫度計及機械攪拌之三頸燒瓶。加入濃氫氯酸(3 4 毫升)且將該混合物在攪拌下加熱至4 5 -_ 5 Ot:二十四 小時。然後在真空下去除水分,留下厚泥狀物其在冷卻至 5 t時形成結晶。加入丙酮(2 0 0毫升)且攪拌幾分鐘 ,在這之後,該固體被濾出且丟棄。丙酮被冷卻至0°C且 固體被濾出。此固體在5 0 0毫升丙酮中沖洗且空氣乾燥 1 8小時,以產生3 1 . 5克之亞乙基雙乙醯胺。 下一步驟包括自亞乙基雙乙醯胺製備乙烯乙醯胺。亞 乙基雙乙醯胺(3 1.05克),碳酸鈣(2克)及矽藻 土5 4 1 ( 2克)置於5 0 0毫升裝有溫度計,機械攪拌 ,及在Vigrmix管柱頂端上蒸餾加熱之三頸燒瓶◊該混合 物經由加熱燒瓶至18〇 — 2 2 5 t:在24mm Hg下 進行真空蒸餾。只有收集到單一部份(1 0 . 8克)’其 包括除了產物外之大部分之乙醯胺(經由NMR測定)0 該固體產物被溶解於異丙醇(3 0毫升)以形成使用作爲 聚合作用之粗乙烯乙醯胺。 混合粗乙烯乙醯胺溶液(1 5毫升),二乙醯苯(工 克,工業等級,5 5 %純度,混合同分異構物),及A ί Β Ν ( 〇 .3克)及在氮氣下加熱回流9 0分鐘’以形成 固體沉澱物。冷卻該溶液,加入異丙醇(5 0毫升)’且 經由離心收集固體。該固體以異丙醇沖洗雨次,以水沖洗 一次,及在真空烘箱乾燥以產生0 · 8克聚(乙烯乙烯胺 :),其被使用於製備聚(乙烯胺◊ 聚(乙烯乙烯胺)(0.79克)備置入1〇〇毫升 __10 '本紙張尺度適用不國國家標準(CNS ) Α4規格(210X297公釐) (請先閱讀背面之注意事項再填寫本頁)
526063 A7 B7 五、發明説明(g ) 之包含水(2 5毫升)及濃氫氯酸(2 5毫升)的單頸燒 瓶中。將該混合物回流5天,在這之後,濾出固體,以水 沖洗一次,以異丙醇沖洗兩次,及在真空烘箱乾燥以產生 0 . 7 7克之產物。紅外線光譜指示仍有明顯量的醯胺( 1 6 5 6 c in一 1 )及少量胺(1 6 0 6 c m —1 )形成。 此反應之產物(〜〇 . 8 4克)被懸浮於氫氧化鈉(4 6 克)及水(4 6克)中且加熱至沸騰(〜1 4 CTC)。由 於起沬,將温度降低且維持在〜1 0 Ot二小時。加入水 (1 0 0毫升)及過濾收集固體。在以水沖洗一次後,該 固體被懸浮在水(5 0 0毫升)中且以醋酸調整p Η値至 ρ Η 5。該固體被再一次濾出,以水沖洗,然後以異丙醇 沖洗,及在真空烘箱乾燥以產生0 · 5 1克產物。紅外線 光譜顯示明顯的胺已形成。 2、聚(醯丙胺)氫氯化物之製備 加入濃氫氯酸(3 6 0毫升)至一個2升,裝置有( 1 )頂端有氮氣入口之冷凝器,(2 )溫度計,及(3 ) 機械攪拌子之水套反應鍋。使用在該反應鍋之套內的循環 水(水溫度=0°C)將該酸冷卻至之5°C ◊在攪拌下將烯 丙胺(3 2 8 · 5毫升,2 5 0克)逐滴加入且保持反應 溫度在5 — 1 0 °C ◊在添加完成後,去除該混合物,置入 3升之單頸燒瓶,且經由在6 0 °C旋轉真空蒸發而去除2 0 6克之液體。然後加入水(2 0毫升)且將該液體置回 反應鍋內◊然後加入懸浮於1 1毫升水之偶氮基雙(甲胖 _______11 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) (請先閱讀背面之注意事項再填寫本頁)
526063 A7 ___________ B7 五、發明説明(?) 基丙烷)二氫氯化物(0 ‘5克)。該產生之反應混合物 在氮氣下加熱至5 0 t:且攪拌2 4小時。然後添加額外的 懸浮於1 1毫升水之偶氮基雙(甲胖基丙烷)二氫氯化物 V 5毫升),在追之後,持續加熱及攪拌額外之4 4小時 在此時間之終點,蒸餾水(.1 〇 〇毫升)被加入至該 反應混合物且使該液體混合物攪拌冷卻。然後去除該混合 物且置於一個2升之分液漏斗中,在這之後,其被逐滴加 入至一甲醇(4升)之攪拌溶液中,以造成固體形成。該 固體經由過濾去除,於甲醇(4升)內再懸浮,攪拌1小 時,及經由過濾收集。然後再一次以甲醇沖洗且該固體在 真空烘箱乾燥以產生2 1 5 . 1克粒狀白色固體之聚(烯 丙胺)氫氯化物。 3、聚(烯丙胺)氫氯化物與表氯醇交聯之製備 加入如實施例2之描述所製備之聚(烯丙胺)氫氯化 物(:1公斤)及水(4升)至一個5加侖的容器中。攪拌 該混合物以溶解該氫氯化物且經由添加固態氫氧化鈉(2 8 4克)調整p Η値。該產生之溶液被冷卻至室溫,在這 之後’在攪拌下一次加入表氯醇交聯劑(5 0毫升)。輕 輕地擾拌該產生之混合物直到其膠質化(約3 5分鐘)。 使該交聯反應在室溫下進行額外之1 8小時,在這之後, 去除該聚合物膠且以數個部分與總共1〇升水置入一個混 合器內。每一部份被輕輕地混合三分鐘以形成粗粒,其然 __________12 中國家標準(CNS ) Α4規格(210X297公釐Γ (請先閱讀背面之注意事項再填寫本頁) 訂 526063 A7 B7 五 '發明説明( ΙΌ 後攪拌1小時且經由過濾收集。該固體經由於水(1 0升 ’ 1 5升,2 0升)中懸浮而被沖洗三次,攪拌每一個懸 浮液1小時,且每一次經由過濾收集固體。該產生之固體 然後經由在異丙醇(1 7升)中懸浮而被沖洗一次,攪拌 該混合物1小時,且然後經由過濾收集固體,在這之後, 該固體在5 0°C之真空烘箱乾燥1 8小時以產生6 7 7克 粒狀,脆的白色固體之交聯聚合物。 部 中 -失 h 消 竹 卬 4、聚(烯丙胺)氫氯化物與丁二醇二縮水甘油醚交聯之 製備 加入如實施例2之描述所製備之聚(烯丙胺)氫氯化 物(5 0 0克)及水(2升)至一個5加侖的容器中。攪 拌該混合物以溶解該氫氯化物且經由添加固態氫氧化鈉( 1 3 4 · 6克)調整p Η値至ρ Η 1 〇。該產生之溶液在 谷器內被冷卻至至溫’在追之後,在擾拌下--·次加入1, 4一丁二醇二縮水甘油醚交聯劑(65毫升)。輕輕地攪 拌該產生之混合物直到其膠質化(約6分鐘)。使該交聯 反應在室溫下進行額外之1 8小時,在這之後,去除該聚 合物膠且在7 5 °C之真空烘箱內乾燥2 4小時。該乾燥固 體然後被磨碎且過篩至_ 3 0孔,在這之後,其被懸浮在 6加侖水中且攪拌1小時。然後濾出固體且再重覆進行沖 洗兩次◊該產生之固體然後空氣乾燥4 8小時,接著在5 O t之真空烘箱乾燥2 4小時以產生4 1 5克白色固體之 交聯聚合物。 13 (讀先閱讀背面之注意事項再填寫本頁)
本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) 526063 A7 B7 s j 合 竹 印
五、發明説明(丨I 5、 聚(烯丙胺)氫氯化物與乙二醇二縮水甘油醚交聯之 製備 加入如實施例2之描述所製備之聚(烯丙胺)氫氯化 物C 1 0克)及水(4 0毫升)至一個1 0 0毫升的燒杯 中。攪拌該混合物以溶解該氫氯化物且經由添加固態氫氧 化鈉調整p Η値至ρ Η 1 〇。該產生之溶液在燒杯內被冷 卻至室溫,在這之後,在攪拌下一次加入1,2 —乙二醇 二縮水甘油醚交聯劑(2.0毫升)。輕輕地攪拌該產生 之混合物直到其膠質化(約4分鐘)◊使該交聯反應在室 溫下進行額外之1 8小時,在這之後,去除該聚合物膠且 在5 0 0毫升之甲醇內混合。然後濾出固體且在水(5 0 0毫升)中被懸浮。在攪拌1小時後,濾出固體且重覆沖 洗步驟。該產生之固體然後經由在異丙醇(4 0 0毫升) 中沖洗兩次及然後在5 0°C之真空烘箱乾燥2 4小時以產 生8 .7克白色固體之交聯聚合物。 6、 聚(烯丙胺)氫氯化物與丁二酸二甲酯交聯之製備 加入如實施例2之描述所製備之聚(烯丙胺)氫氯化 物(10克),甲醇(10 0毫升),及三乙胺(10毫 升)至一個5 0 0毫升的圓底瓶中’攪拌該混合物模加入 丁二酸二甲酯交聯劑(1毫升)。加熱該溶液至回流且在 3 0分鐘後,中斷攪拌。在1 8小時後,該溶液被冷卻至 室溫,且濾出固體及以4 0 0毫升異丙醇混合。然後濾出 14 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) --------------訂------ (請先閱讀背面之注意事項再填寫本頁) 526063 A7 B7 五、發明説明() (請先閱讀背面之注意事項再填寫本頁) 固體且在水(1升)中被懸浮。在攪拌1小時後,濾出固 體且重覆沖洗步驟兩次。該固體以異丙醇(8 0 0毫升) 沖洗一次及然後在5 Ot:之真空烘箱乾燥2 4小時以產生 5 . 9克白色固體之交聯聚合物。 聚(烯丙胺)氫氯化物(5 0 . 7 %水溶液5 5 0磅 )之水溶液以水(7 5 1磅)稀釋且以氫氧化鈉水溶液( 5 0 %水溶液1 7 1磅)中和。該溶液冷卻至約2 5 t:且 加入乙膳(1 3 4 0磅)及表氯醇(2 6 . 2磅)。劇烈 攪拌該溶液2 1小時。在這段期間內,該反應器內容自兩 液相改變至於液體內之泥狀粒子。經由過濾分離固態膠產 物。該膠以一種滔出方法用水(1 3 6,7 0 8磅)淸洗 。經由過濾分離該膠且以異丙醇沖洗。該膠與異丙醇(1 2 6 9磅)混合且經由過濾分離。該異丙醇/水溼膠在6 0 °C真空乾燥器內乾燥。磨碎該乾燥產物以通過5 0篩孔 以獲得適合作爲藥理用途之產物(1 6 6磅,7 3 %。 7、人體中血淸膽固醇之作用 於鈣及/‘或鋁基質磷酸鹽黏合劑穩定劑量之血液透析 患者參與一星期篩選期。中斷該磷酸鹽黏合劑。 那些顯示血磷酸鹽過多(血淸P 0 4 > 6 ·0 m g / d L )之患者,在沖洗(Wash-out)期間,合適作藥物治 療。一種RenaGel0黏合劑(表氯醇交聯聚醯丙胺, GelTex Pharmaceutical,Inc.,Waltham,MA)起始劑量 爲基於血磷酸過多的程度而定。起始劑量爲每天三次二, _______15___ 本紙張尺度適用中國國家標準(CNS ) A4規格(210X 297公釐) 526063 A7 B7 五、發明説明(Λ ) (請先閱讀背面之注意事項再填寫本頁) 三,或四個4 6 5毫克之膠囊用餐服用。在每一個三星期 最後之接下來的二星期期間,RenaGel®黏合劑之劑量增加 爲每餐一個膠囊作爲必須達到血淸磷包含在2 . 5及5 . 5 m g / d L之間。若血淸磷降至少於2 · 5 m g / d L, 該RenaGel0黏合劑劑量減少爲每天依至三個膠囊以提高 血淸磷至2 · 5 m g / d L以上。 在此硏究中,當血淸鈣降至低於正常(經由主要實驗 正常範圍所定義)時,該血淸鈣等級經由於就寢時間在空 胃中添加達1 0 0 0毫克作爲碳酸鹽之元素鈣的晚間鈣供 給或透增加析液鈣濃度而恢復至正常範圍內◊供給包含3 0 0毫克元素鈣之7 5 0毫克TUMS EX®錠劑。若患者較 適合另外配方,可使用其他品牌之碳酸鈣或醋酸鈣。 在治療期間的最後,任何殘留的RenaGel®膠囊被取 回且患者被避開磷酸鹽黏合劑兩星期◊在這第二次沖洗期 間,患者中斷任何晚間鈣供給且恢復其原來的磷酸鹽黏合 劑。 在這段期間每週一次,於星期一(MWF患者)及星期 二(TTS患者),就在透析之前,這些患者提供血液作爲 實驗室硏究。在同一週之星期三(MWF患者)及星期四( TTS患者),研究者詢問患者是否有體驗任何不良結果或 改變藥物治療,其可顯示出不良結果及回顧實驗室試驗之 結果。 在於第一次沖洗治療,第二次沖洗期間選定的日子, 由來自麻薩諸塞州醫學中心大學(University of __Ιό 本紙張尺度適用中國國家標準(CNS ) Α4規格(210X297公釐) 526063 A7 B7 五、發明説明(A )
Massachusetts Medical Center)之營養學家藉由 2 4 小時 回憶方法評估磷之飲食攝入。 大約216個於磷酸鹽黏合劑穩定劑量之血液透析患 者參與此硏究。該患者必須具有良好控制血淸磷及不具有 任何臨床上不穩定之醫學狀況。只有那些血磷酸鹽過多C 血淸P 〇 4 > 6 . 0 m g / d L :)之患者,在第一次沖洗 期間(大約180個患者),接受治療。 該聚合物以包含5 0 0毫克聚合物之膠嚢供給。每一 個患者開始於三種聚合物劑量之一種:(i )每天三次2 個膠囊(0 .9 3克)用餐服用:(i i )每天三次3個 膠囊C 1 . 4克)用餐服用;及(i i i )每天三次4個 膠囊(I 8 6克)用餐服用。 (讀先閱讀背面之注意事項再填寫本頁) Φ.
、1T 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) 526063 A7 7 Β 五、發明説明(A ) 全部 I 劑童等級^低 …~~Ί~~ ~! I —…~~=. 參數 訪問 1 N 革均 標準偏差 Ρ-値’ Ν 平均 標準偏差I 總膽固醇 (mg/dL) 1 28 214,6 4Κ2 13 217.0 42.4 | 1 I 2 29 221.7 35.6 13 216.5 35.0 6 28 182.2 46.2 ! 12 186.8 44.1 ! ίο 25 184/7 48.5 12 195.5 47.7 ] 10/最終 25 184/7 48.5 12 ! 195.5 47刀 改變(10/最終 -2) :25 λ η λ -/ . Ζ 29.0 <0.0001 12 -22.3 27.3 1 12 25 208.1 42.1 12 202,6 38,4 改變(12-10) 24 23.1 34.2 0.0006 12 1Λ 40.7 LDL膽固醇 (mg/clL) -1 27 145.0 34.1 12 147.2 32.2 2 29 154.6 27.4 13 147.4 16.3 6 28 110.5 33.4 12 113.3 32.4 10 25 109.0 37.7 12 109.5 34.6 10/最終 25 109.0 37.7 12 109‘5 34.6 改變(10/最終 -2) 25 -45.7 29.3 <0.0001 12 -38,0 29.0 12 25 141.0 33,6 12 132.3 20.9 改變(12-10) 24 33,0 24.8 <0.0001 12 22.8 23.6 (讀先閱讀背面之注意事項再填寫本頁) 18 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) 526063 A7 B7 五、發明説明(少) i 劑量等級W中 劑量等級w高 參敷 N丨平均 標準偏差 N 平巧 標準偏差 總膽固醇 (mg/dL) -1 3 267.3 57.4 12 198.8 23,8 0.0978 2 4 261,8 46,1 12 214,0 25,1 i 0.0790 6 4 234,8 63.1 12 160/1 25.6 0.0222 10 4 223.5 52.9 9 153.1 29.0 0.0181 10/最終 4 223.5 52,9 ! 9 153.1 29.0 0,0181 改變(i0/最終 :-2) 丨4 -38.3 | 25,3 ! | ! ! 9 -56.7 | 22 J 0.0098 1 12 :4 267.3 45.6 9 189.2 | 18.0 0,0291 改變(12-10) 4 43.8 12,9 8 | 36.8 16.2 0.0306 LDL膽固醇 (mg/dL) -1 3 191.1 40.2 12 | 1 I 131.2 24.9 0,0494 2 4 184.6 46.2 12 152.3 25.3 0.1441 6 4 150.5 43,9 12 94,5 17,3 0.0085 10 4 141.0 45.6 9 94.2 32.7 0.1750 10/最終 4 141.0 45.6 9 94.2 32.7 0.1750 改變(10/最終: -2) 4 -43.6 28,0 9 -56.8 ! 29.9 ! 0.2972 •卜Λ 丄Ζ 4 194.2 37.9 9 129.0 23.8 0.0221 改變(12-10) 4 53.2 17.9 8 38.2 23.9 ! 0.0503 (請先閲讀背面之注意事項再填寫本頁 费_ 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) 526063
7 7 A B 五、發明説明(η ) 全部 劑量等級> “低! 參敷 訪問 Ν ZlSf 与 標準偏差 P-値y N 平均 標準偏差 HDL膽固醇 (nig/dL) Ί 27 37.6 9.4 12 | ! 39.6 i(U ί ί j 29 1 36,4 9.2 13 1 | 37,8 9.8 6 28 38.5 10.5 12 ! 40.3 13.1 10 25 36.5 11‘1 ; ! I 1 ί 12 : 41.3 12.0 | K)/最終i ! ! ·〇 | | 36.5 ! 11.1 ' I | 12 1 ί 4L3 i 12.0 改變(10/最終1 1-2) 1 25 ;I 0.8 9.0 0.2823 12 | I ! 2.8 1 10.3 ! 12 j 25 38.6 ! 11/3 12 42.G 10.1 改變(12-10) 24 0.9 8.5 0.8018 12 0.7 7.7 三甘油脂: (mg/dL) |-1 1 28 165.8 80.5 13 164· 7 93.9 | 2 29 153.9 92.3 13 156.3 103.7 6 28 165.5 89.5 12 ! 165.7 1 80.8 10 25 | 196.2 165.3 12 223.4 222.6 10/最終 25 196.2 165.3 12 223,4 222.6 | 改變(10/最終 μ) 25 38.2 150.6 0.3161 丨 12 1 64.3 214.4 12 ! 25 142,5 9L2 12丨 141,7 107.2 改變(12-10) t- -54.0 151.3 0.0135 丄Ζ -81.8 209.6 (請先閱讀背面之注意事項再填寫本頁) ·#今
、1T L0. 本紙張尺度適用中國國家標準(CNS ) Α4規格(210X297公釐) 526063 A7 B7 五、發明説明(J ) 劑量等級1 抑中 劑量等級^高 參數 訪問 N 卒均I標準偏差 Ν i 平均 標準偏差 Ρ嘗 HDL膽固醇 (mg/dD 3 32.7 ! S 1 /1 7 ί - 〇 丨 / 丨 丄乂 丨! 36.8 9,6 0.5108 2 I 4 31,3 5,0 : 12 36,5 9,6 0,4077 6 1 4 37.0 7.4 12 37,3 8.6 0,6622 10 I 4 34,5 6.1 9 30.9 1 9J 丨 i 0,1053 10/最終 4 34,5 6.1 9 30,9 : i 9.3 ! 0,1053 改變(10/最終1 4 ~2) ! ! 3.3 3.0 9 -3,0 8.2 0.1000 1 12 4 ; 35.5 ! 5.3 ί 9 35,6 14.2 0.1986 改變(12-10) | ! ~~~Γ 4 | 1,0 i 2.7 | 8 1.3 11.8 i 0.7914 三甘油脂 (mg/dL) -1 3 | 217.7 I 113.0 1 12 153.9 55,3 ! 0.5796 9. 4 229.5 104.0 12 126.2 64.0 0.2165 h 4 236.5 123.4 12 141,7 80.7 0.2408 10 240.0 65.1 9 140.3 8L8 0.0994 10/最終 4 240.0 65.1 9 140.3 8L8 0.0994 改變(10/最終 -2) 4 10,5 55.2 ! 9 ! 15.8 4L0 0.9199 i 丄Ζ 4 188.0 76.3 9 123.4 〜.λ /4.1 0,2964 ! 1 改變(12-10) 4 -52.0 34.7 8 -3,4 49.7 0.2320 (請先閱讀背面之注意事項再填寫本頁) 、11 L0. ^ Wilcoxon Signed Rank Test Kruskal-Wallis Exact Test ***在硏究期間使用最後實際量所定義之劑量等級 8、於健康年輕及老年,男性與女性志願者之作用 八個年輕(1 9 一 4 0歲)及八個老年(6 5歲或更 老)健康志願男性及女性患者接受2 · 3 2 5克RenaGd®黏 "^氏張尺度適用中國國家標準(〔灿)八4規格(210父297公釐) __21_ 526063 A7 B7 五、發明説明(ll) 合劑(表氯醇交聯聚烯丙胺)每天三次用餐服用3 2天。 所有的藥物劑量與餐施用由臨床硏究中心供給整個3 2天 硏究。在第0天,在早餐前取岀1 0毫升血液樣本且分析 血漿膽固醇等級。在第3 2天,在早餐前取出第二個1 0 毫升血液樣本。在第3 2天早餐後,試驗者被解除硏究。 測量血槳三甘油脂及HDL且經由Fdedewald式計算LD L膽固醇。 圖表顯示聚合物在相對於基線L D L膽固醇之L D L 膽固醇的作用。在這些正常志願者的基線膽固醇愈高,在 L D L膽固醇之下降愈大。在整個1 6個患者群體中之L D L膽固醇下降之平均値爲4 2mg / d L。在此硏究中 之5個患者具有低於1 0 0 m g/d L之基線L D L膽固 醇。在1 1個具有基線L D L膽固醇>· 1 2 0 m g / d L 之患者於L D L膽固醇下降爲5 2 . 5 m g/d L。 同等物 當以其較佳具體實施例作爲參考而特別顯示及描述本 發明時,其將了解習於此技藝人士在其中形式或細節中所 作之不同的改變,將不會背離如附加在本發明之申請專利 範圍所定義之精神與範疇。 2.2 (請先閱讀背面之注意事項再填寫本頁)
、1T 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐)
Claims (1)
- 526063 A8 B8 C8 D8 六、申請專利範圍 爲1。 (請先閱讀背面之注意事項再填寫本頁) 7、 根據申請專利範圍第5項之醫藥組成物,其中X 爲0。 8、 根據申請專利範圍第1項之醫藥組成物,其包括 一種以下式之重覆單元表示之經交聯同聚烯丙胺聚合物: —fH2c—广七 CHZ NH2 ο 9、 根據申請專利範圍第8項之醫藥組成物,其中該 經交聯同聚丙烯胺係藉由多功能交聯劑而交聯,該交聯劑 以基於單體與交聯劑之組合重量爲基礎,其量爲自約1 -2 5 %之重量百分比存在。 1 0、根據申請專利範圍第9項之醫藥組成物,其中 該交聯劑以基於單體與交聯劑之組合重量爲基礎,其量爲 自約2.5 - 2 0%之重量百分比存在。 經濟部智慧財產局員工消費合作社印製 1 1、根據申請專利範圍第1 0項之醫藥組成物,其 中該交聯劑包括表氯醇(epichlorohydrin)。 1 2、根據申請專利範圍第1項之醫藥組成物,其包 括一種以下式之重覆單元表示之交聯同聚乙烯胺聚合物: -fH〇C ——ChA— ΝΗ^ ο 2 __ 本紙張尺度適用中國國家標準(CNS)A4規格(210 χ 297公釐) 526063 A8 B8 C8 D8 々、申請專利範圍 1 3、根據申請專利範圍第1 2項之醫藥組成物,其 中該經交聯同聚乙烯胺係藉由多功能交聯劑而交聯,該交 聯劑以基於單體與交聯劑之組合重量爲基礎,其量爲自約 1 一 2 5 %之重量百分比存在。 1 4、根據申請專利範圍第1 3項之醫藥組成物,其 中該交聯劑以基於單體與交聯劑之組合重量爲基礎,其量 爲自約2.5 - 2 0%之重量百分比存在。 1 5、根據申請專利範圍第1 4項之醫藥組成物,其 中該交聯劑包括表氯醇(epichlorohydrin)。 --------------------^--------- (請先閱讀背面之注意事項再填寫本頁) 經濟部智慧財產局員工消費合作社印製 3 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐〉
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US87842297A | 1997-06-18 | 1997-06-18 | |
US92724797A | 1997-09-11 | 1997-09-11 | |
US08/979,096 US6423754B1 (en) | 1997-06-18 | 1997-11-26 | Method for treating hypercholesterolemia with polyallylamine polymers |
Publications (1)
Publication Number | Publication Date |
---|---|
TW526063B true TW526063B (en) | 2003-04-01 |
Family
ID=27420493
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW087109749A TW526063B (en) | 1997-06-18 | 1998-07-09 | Pharmaceutical composition for use in removing bile salts |
Country Status (16)
Country | Link |
---|---|
US (3) | US6423754B1 (zh) |
EP (1) | EP0996454B1 (zh) |
JP (1) | JP4420143B2 (zh) |
KR (1) | KR100567751B1 (zh) |
CN (1) | CN1211091C (zh) |
AT (1) | ATE249228T1 (zh) |
AU (1) | AU735260C (zh) |
CA (1) | CA2294036C (zh) |
DE (1) | DE69818058T2 (zh) |
HK (1) | HK1029920A1 (zh) |
IL (1) | IL133434A (zh) |
MX (1) | MXPA99011826A (zh) |
MY (1) | MY125874A (zh) |
NZ (1) | NZ501719A (zh) |
TW (1) | TW526063B (zh) |
WO (1) | WO1998057652A1 (zh) |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW568788B (en) * | 1998-10-12 | 2004-01-01 | Chugai Pharmaceutical Co Ltd | Polymer combining with phosphoric acid and preparation containing the same |
EP1293211A1 (en) * | 1998-12-23 | 2003-03-19 | G.D. Searle LLC. | Combinations of ileal bile acid transport inhibitors and bile acid sequestering agents for cardiovascular indications |
CA2362410A1 (en) * | 1999-04-16 | 2000-10-26 | Abbott Laboratories | Process for producing cross-linked polyallylamine hydrochloride |
US6362266B1 (en) | 1999-09-03 | 2002-03-26 | The Dow Chemical Company | Process for reducing cohesiveness of polyallylamine polymer gels during drying |
US6180754B1 (en) | 1999-09-03 | 2001-01-30 | The Dow Chemical Company | Process for producing cross-linked polyallylamine polymer |
US20020054903A1 (en) * | 1999-10-19 | 2002-05-09 | Joseph Tyler | Direct compression polymer tablet core |
US6733780B1 (en) | 1999-10-19 | 2004-05-11 | Genzyme Corporation | Direct compression polymer tablet core |
EP1911462A3 (en) | 2001-01-26 | 2011-11-30 | Schering Corporation | Compositions comprising a sterol absorption inhibitor |
WO2002085379A1 (en) * | 2001-04-18 | 2002-10-31 | Geltex Pharmaceuticals, Inc. | Method for improving vascular access in patients with vascular shunts |
AU2002257145B2 (en) | 2001-04-18 | 2005-06-02 | Genzyme Corporation | Method for lowering serum glucose |
CA2444028A1 (en) | 2001-04-18 | 2002-10-31 | Genzyme Corporation | Methods of treating syndrome x with aliphatic polyamines |
DE60212819T2 (de) * | 2001-04-18 | 2006-11-23 | Genzyme Corp., Cambridge | Salzformarme polyallylamine |
JP2005510524A (ja) * | 2001-11-16 | 2005-04-21 | アルス・セラピー・デベロツプメント・フアンデーシヨン・インコーポレーテツド | ポリアミン経路の調節による神経変性障害の治療 |
AU2003282867A1 (en) * | 2002-10-22 | 2004-05-13 | Genzyme Corporation | Amine polymers for promoting bone formation |
US7459502B2 (en) * | 2003-11-03 | 2008-12-02 | Ilypsa, Inc. | Pharmaceutical compositions comprising crosslinked polyamine polymers |
US7767768B2 (en) * | 2003-11-03 | 2010-08-03 | Ilypsa, Inc. | Crosslinked amine polymers |
US7385012B2 (en) * | 2003-11-03 | 2008-06-10 | Ilypsa, Inc. | Polyamine polymers |
US7449605B2 (en) * | 2003-11-03 | 2008-11-11 | Ilypsa, Inc. | Crosslinked amine polymers |
US7335795B2 (en) * | 2004-03-22 | 2008-02-26 | Ilypsa, Inc. | Crosslinked amine polymers |
US7608674B2 (en) * | 2003-11-03 | 2009-10-27 | Ilypsa, Inc. | Pharmaceutical compositions comprising cross-linked small molecule amine polymers |
EP1689383B1 (en) | 2003-11-19 | 2012-10-31 | Metabasis Therapeutics, Inc. | Novel phosphorus-containing thyromimetics |
PL2269589T3 (pl) | 2004-03-30 | 2014-05-30 | Relypsa Inc | Polimery wiążące jony i ich zastosowania |
US20050244367A1 (en) * | 2004-05-03 | 2005-11-03 | Ilypsa, Inc. | Phospholipase inhibitors localized in the gastrointestinal lumen |
US20050276781A1 (en) * | 2004-06-09 | 2005-12-15 | Ross Edward A | Molecularly imprinted phosphate binders for therapeutic use |
US7985418B2 (en) * | 2004-11-01 | 2011-07-26 | Genzyme Corporation | Aliphatic amine polymer salts for tableting |
US20060177415A1 (en) * | 2004-11-01 | 2006-08-10 | Burke Steven K | Once a day formulation for phosphate binders |
CA2601236A1 (en) * | 2005-03-16 | 2006-09-21 | Usv Limited | An improved process for the preparation of crosslinked polyallylamine polymer |
US20090028925A1 (en) | 2005-05-26 | 2009-01-29 | Erion Mark D | Novel Phosphinic Acid-Containing Thyromimetics |
WO2007027566A2 (en) | 2005-09-02 | 2007-03-08 | Genzyme Corporation | Method for removing phosphate and polymer used therefore |
AR056499A1 (es) * | 2005-09-06 | 2007-10-10 | Serapis Farmaceuticals Ltd | Compuestos |
BRPI0616078B8 (pt) | 2005-09-15 | 2021-05-25 | Genzyme Corp | pó de uma formulação farmacêutica de polímero de amina, uso de tal pó e formulação em sachê para polímeros de amina |
EP2016114A2 (en) * | 2006-05-05 | 2009-01-21 | Genzyme Corporation | Amine condensation polymers as phosphate sequestrants |
US20100124542A1 (en) * | 2006-07-18 | 2010-05-20 | Genzyme Corporation | Amine dendrimers |
WO2008042222A2 (en) | 2006-09-29 | 2008-04-10 | Genzyme Corporation | Amide dendrimer compositions |
EP2076286B1 (en) * | 2006-10-25 | 2016-03-09 | Wisconsin Alumni Research Foundation | Methods of reducing phosphate absorption using an anti-npt2b antibody |
CA2667563A1 (en) * | 2006-10-26 | 2008-05-02 | Wisconsin Alumni Research Foundation | Methods of reducing phosphate absorption |
BRPI0720234A2 (pt) * | 2006-12-14 | 2013-12-24 | Genzyme Corp | Composição farmacêutica |
PT2124884T (pt) | 2006-12-22 | 2019-09-17 | Ironwood Pharmaceuticals Inc | Composições compreendendo sequestradores de ácido biliar para tratar distúrbios esofágicos |
WO2008103368A1 (en) * | 2007-02-23 | 2008-08-28 | Genzyme Corporation | Amine polymer compositions |
EP2131820A1 (en) * | 2007-03-08 | 2009-12-16 | Genzyme Corporation | Sulfone polymer compositions |
WO2008133954A1 (en) * | 2007-04-27 | 2008-11-06 | Genzyme Corporation | Amido-amine dendrimer compositions |
US20100316589A1 (en) * | 2007-12-14 | 2010-12-16 | Hitesh Bhagat | Coated Pharmaceutical Compositions |
PA8807201A1 (es) * | 2007-12-14 | 2009-07-23 | Genzyme Corp | Composiciones farmaceuticas |
WO2009154747A1 (en) * | 2008-06-20 | 2009-12-23 | Genzyme Corporation | Pharmaceutical compositions |
US8404784B2 (en) * | 2008-12-03 | 2013-03-26 | Navinta Llc | Manufacturing process of making polymeric amine salts |
US20120046364A1 (en) | 2009-02-10 | 2012-02-23 | Metabasis Therapeutics, Inc. | Novel Sulfonic Acid-Containing Thyromimetics, and Methods for Their Use |
IT1394299B1 (it) * | 2009-05-12 | 2012-06-06 | Chimico Internaz Spa Lab | Procedimento per la preparazione di sevelamer |
JP5285000B2 (ja) * | 2010-02-23 | 2013-09-11 | 富士フイルム株式会社 | 低密度リポ蛋白コレステロールの測定方法 |
WO2012027331A1 (en) | 2010-08-27 | 2012-03-01 | Ironwood Pharmaceuticals, Inc. | Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders |
WO2014057522A1 (en) | 2012-10-12 | 2014-04-17 | Mochida Pharmaceutical Co., Ltd. | Compositions and methods for treating non-alcoholic steatohepatitis |
US10441560B2 (en) | 2013-03-15 | 2019-10-15 | Mochida Pharmaceutical Co., Ltd. | Compositions and methods for treating non-alcoholic steatohepatitis |
JP6442412B2 (ja) | 2013-03-15 | 2018-12-19 | 持田製薬株式会社 | 非アルコール性脂肪性肝炎治療のための組成物および方法 |
CN112047854B (zh) * | 2020-10-20 | 2021-07-02 | 中国科学院长春应用化学研究所 | 一种n-乙烯基烷基酰胺的制备方法 |
Family Cites Families (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB798488A (en) | 1956-01-09 | 1958-07-23 | Nat Aluminate Corp | Quaternary ammonium compounds and method for the preparation thereof |
US2874132A (en) | 1956-11-02 | 1959-02-17 | Rohm & Haas | Anion-exchange resins for sugar decolorization and their preparation |
BE580490A (fr) | 1958-07-15 | 1960-01-08 | Merck & Co Inc | Compositions et procédés pour abaisser la teneur en cholestérol du sang |
US3383281A (en) | 1961-09-22 | 1968-05-14 | Merck & Co Inc | Method for binding bile acids in vivo |
US3308020A (en) | 1961-09-22 | 1967-03-07 | Merck & Co Inc | Compositions and method for binding bile acids in vivo including hypocholesteremics |
US3288770A (en) | 1962-12-14 | 1966-11-29 | Peninsular Chem Res Inc | Water soluble quaternary ammonium polymers |
CH486202A (de) | 1966-05-31 | 1970-02-28 | Agripat Sa | Mikrobizides Mittel |
US3562266A (en) | 1969-05-26 | 1971-02-09 | Montedison Spa | Quaternary ammonium halides having a 2-chloro cyclohexyl or 2-chloro alkyl substituent |
BE756035A (fr) | 1969-09-12 | 1971-03-11 | Inveresk Res Int | Polymeres pontes |
US3803237A (en) | 1969-11-03 | 1974-04-09 | Upjohn Co | Reaction products of polyethylenepolyamines and chlorohydrins or epoxy containing compounds |
NL7017227A (zh) | 1969-12-27 | 1971-06-29 | ||
US3692895A (en) | 1970-09-08 | 1972-09-19 | Norman A Nelson | Method of reducing hypercholesteremia in humans employing a copolymer of polyethylenepolyamine and a bifunctional substance, such as epichlorohydria |
US3980770A (en) | 1971-06-04 | 1976-09-14 | Pharmacia Aktiebolag | Polymerization products containing amino groups useful in serum cholesterol level control |
US4205064A (en) | 1973-06-11 | 1980-05-27 | Merck & Co., Inc. | Bile acid sequestering composition containing poly[{alkyl-(3-ammoniopropyl)imino}-trimethylenedihalides] |
US4027009A (en) | 1973-06-11 | 1977-05-31 | Merck & Co., Inc. | Compositions and methods for depressing blood serum cholesterol |
US4217429A (en) | 1973-06-11 | 1980-08-12 | Merck & Co., Inc. | Poly-[(methylimino)trimethylene] |
CS187563B1 (en) | 1974-02-08 | 1979-02-28 | Petr Strop | Method of preparation of the hydrophilic homogeneous or macroporous annexes |
CS173201B1 (zh) | 1974-02-13 | 1977-02-28 | ||
US4016209A (en) | 1975-04-23 | 1977-04-05 | Merck & Co., Inc. | 3-[N'-(3-Halopropyl)-N-'-methylamino]-N,N,N-trimethyl-1-propanaminium halide and acid addition salts thereof |
US4071478A (en) | 1976-06-07 | 1978-01-31 | Merck & Co., Inc. | Controlled partially cross-linked 3,3-ionenes |
FI67483C (fi) | 1977-02-17 | 1985-04-10 | Merck & Co Inc | Foerfarande foer framstaellning av ett icke adhesivt friflytande farmakologiskt godtagbart gallsyrakomplexbildande adsorbatpreparat |
IT1106718B (it) | 1978-12-21 | 1985-11-18 | Alfa Farmaceutici Spa | Composizioni a base di resine anioniche salificate farmacologicamente attive |
US4426489A (en) | 1980-02-21 | 1984-01-17 | The Dow Chemical Company | Surface active polymeric surfactants containing side chain hydrophobes |
EP0055048B1 (en) | 1980-12-12 | 1985-04-03 | Smith and Nephew Associated Companies p.l.c. | Polymers, preparation and use |
JPS5879022A (ja) | 1981-11-04 | 1983-05-12 | Bitamin Kenkyusho:Kk | 第四級窒素原子を含有する新規な金属架橋高分子化合物、その製法及び該高分子化合物を有効成分とする高脂血症治療剤 |
US4557930A (en) | 1982-01-18 | 1985-12-10 | Mitsubishi Petrochemical Co., Ltd. | Anticholesteremic anion exchange resins |
JPS6090243A (ja) | 1983-10-25 | 1985-05-21 | Nitto Boseki Co Ltd | 小球状モノアリルアミン橋かけ重合体の製造方法 |
US4528347A (en) | 1983-11-10 | 1985-07-09 | 501 Nitto Boseki, Co. Ltd | Process for producing polymers of monoallylamine |
JPS60106803A (ja) | 1983-11-14 | 1985-06-12 | Nitto Boseki Co Ltd | アリル尿素重合体の製造方法 |
EP0142962A3 (en) | 1983-11-14 | 1986-01-15 | Nitto Boseki Co., Ltd. | Process for producing poly (allylamine) derivatives |
CA1220897A (en) | 1984-01-11 | 1987-04-21 | Kiyoshi Shimizu | Process for producing polymers of monoallylamine |
EP0162388B1 (en) | 1984-05-11 | 1989-09-13 | Bristol-Myers Company | Novel bile sequestrant resin and uses |
US4759923A (en) | 1987-06-25 | 1988-07-26 | Hercules Incorporated | Process for lowering serum cholesterol using poly(diallylmethylamine) derivatives |
DE3800199A1 (de) | 1988-01-07 | 1989-07-20 | Sandoz Ag | Seitenkettenhaltige vinylpolymere |
GB8829088D0 (en) | 1988-12-13 | 1989-01-25 | Smith Kline French Lab | Compounds |
US5236701A (en) | 1989-07-19 | 1993-08-17 | Lowchol Scientific Inc. | Ingestible hydrophilic polymeric amines useful for lowering blood cholesterol |
GB8928278D0 (en) | 1989-12-14 | 1990-02-21 | Smith Kline French Lab | Compounds |
CA2040996A1 (en) | 1990-05-02 | 1991-11-03 | Robert L. Albright | Composition and method for controlling cholesterol |
GB9011332D0 (en) | 1990-05-21 | 1990-07-11 | Smith Kline French Lab | Compounds |
IE914179A1 (en) | 1990-12-07 | 1992-06-17 | Ici Plc | Nitrogen derivatives |
US5055197A (en) | 1991-04-05 | 1991-10-08 | Rohm And Haas Company | Process for removing residual monomers and oligemers from amine-containing polymers |
JP3247435B2 (ja) | 1992-07-11 | 2002-01-15 | 日産アルティア株式会社 | 芯材添設型樹脂製車両用ルーフレールの製造方法及び車両用ルーフレール |
DE59307535D1 (de) | 1992-07-22 | 1997-11-20 | Hoechst Ag | Hydrophile Zentren aufweisende Polyvinylamin-Derivate, Verfahren zu ihrer Herstellung sowie die Verwendung der Verbindungen als Arzneimittel, Wirkstoffträger und Nahrungsmittelhilfsstoff |
ES2096150T3 (es) | 1992-07-22 | 1997-03-01 | Hoechst Ag | Copolimeros vinilicos reticulados, procedimiento para su preparacion, asi como el empleo de estos compuestos. |
NZ255758A (en) | 1992-08-20 | 1997-10-24 | Du Pont | Crosslinked polymeric ammonium salts useful as bile sequestrants |
US5451397A (en) | 1992-12-21 | 1995-09-19 | Rohm And Haas Company | Bile acid sequestrant |
JPH06321786A (ja) * | 1993-05-12 | 1994-11-22 | Sekisui Chem Co Ltd | 胆汁酸腸管吸収抑制剤 |
US5487888A (en) | 1993-05-20 | 1996-01-30 | Geltex, Inc. | Iron-binding polymers for oral administration |
US5607669A (en) * | 1994-06-10 | 1997-03-04 | Geltex Pharmaceuticals, Inc. | Amine polymer sequestrant and method of cholesterol depletion |
JPH09500368A (ja) | 1993-06-02 | 1997-01-14 | ジェルテックス ファーマシューティカルズ,インコーポレイテッド | 胆汁酸塩を除去するための組成物および方法 |
US5624963A (en) * | 1993-06-02 | 1997-04-29 | Geltex Pharmaceuticals, Inc. | Process for removing bile salts from a patient and compositions therefor |
US5618530A (en) | 1994-06-10 | 1997-04-08 | Geltex Pharmaceuticals, Inc. | Hydrophobic amine polymer sequestrant and method of cholesterol depletion |
US5496545A (en) | 1993-08-11 | 1996-03-05 | Geltex Pharmaceuticals, Inc. | Phosphate-binding polymers for oral administration |
US5414068A (en) | 1994-01-24 | 1995-05-09 | Rohm And Haas Company | Crosslinked anion exchange particles and method for producing the particles |
TW474813B (en) | 1994-06-10 | 2002-02-01 | Geltex Pharma Inc | Alkylated composition for removing bile salts from a patient |
US5792749A (en) * | 1997-01-09 | 1998-08-11 | Virginia Commonwealth University | Method and composition for lowering low density lipoprotein cholesterol |
-
1997
- 1997-11-26 US US08/979,096 patent/US6423754B1/en not_active Expired - Lifetime
-
1998
- 1998-06-15 CN CNB988071118A patent/CN1211091C/zh not_active Expired - Lifetime
- 1998-06-15 IL IL13343498A patent/IL133434A/xx not_active IP Right Cessation
- 1998-06-15 AU AU79675/98A patent/AU735260C/en not_active Expired
- 1998-06-15 EP EP98930234A patent/EP0996454B1/en not_active Expired - Lifetime
- 1998-06-15 KR KR1019997011968A patent/KR100567751B1/ko not_active IP Right Cessation
- 1998-06-15 JP JP50464599A patent/JP4420143B2/ja not_active Expired - Lifetime
- 1998-06-15 NZ NZ501719A patent/NZ501719A/en not_active IP Right Cessation
- 1998-06-15 AT AT98930234T patent/ATE249228T1/de not_active IP Right Cessation
- 1998-06-15 DE DE69818058T patent/DE69818058T2/de not_active Expired - Lifetime
- 1998-06-15 CA CA002294036A patent/CA2294036C/en not_active Expired - Lifetime
- 1998-06-15 MX MXPA99011826A patent/MXPA99011826A/es active IP Right Grant
- 1998-06-15 WO PCT/US1998/012422 patent/WO1998057652A1/en active IP Right Grant
- 1998-06-17 MY MYPI98002704A patent/MY125874A/en unknown
- 1998-07-09 TW TW087109749A patent/TW526063B/zh not_active IP Right Cessation
-
2001
- 2001-01-22 HK HK01100549A patent/HK1029920A1/xx not_active IP Right Cessation
-
2002
- 2002-05-29 US US10/158,207 patent/US20030086898A1/en not_active Abandoned
-
2006
- 2006-02-01 US US11/344,862 patent/US20060239959A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
IL133434A0 (en) | 2001-04-30 |
US6423754B1 (en) | 2002-07-23 |
US20030086898A1 (en) | 2003-05-08 |
JP2002516613A (ja) | 2002-06-04 |
US20060239959A1 (en) | 2006-10-26 |
KR100567751B1 (ko) | 2006-04-05 |
CA2294036C (en) | 2007-08-21 |
DE69818058T2 (de) | 2004-07-08 |
NZ501719A (en) | 2001-10-26 |
WO1998057652A1 (en) | 1998-12-23 |
DE69818058D1 (de) | 2003-10-16 |
JP4420143B2 (ja) | 2010-02-24 |
CA2294036A1 (en) | 1998-12-23 |
CN1263468A (zh) | 2000-08-16 |
EP0996454B1 (en) | 2003-09-10 |
AU7967598A (en) | 1999-01-04 |
KR20010013943A (ko) | 2001-02-26 |
HK1029920A1 (en) | 2001-04-20 |
AU735260B2 (en) | 2001-07-05 |
ATE249228T1 (de) | 2003-09-15 |
MXPA99011826A (es) | 2002-07-02 |
IL133434A (en) | 2005-09-25 |
EP0996454A1 (en) | 2000-05-03 |
CN1211091C (zh) | 2005-07-20 |
AU735260C (en) | 2002-03-28 |
MY125874A (en) | 2006-08-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW526063B (en) | Pharmaceutical composition for use in removing bile salts | |
CA2038852C (en) | Ingestible amine functionalized and cross-linked homopolymers with hydrophobic backbone for the lowering of blood cholesterol | |
RU2146266C1 (ru) | Способ секвестрации солей желчных кислот из организма, терапевтическая и полимерные композиции для осуществления этого способа | |
ES2637020T3 (es) | Uso de polímero de amina para reducir la glucosa sérica | |
KR101052581B1 (ko) | 음이온 결합성 중합체 및 그 용도 | |
RU2160742C2 (ru) | Способ выведения желчных камней из организма пациента (варианты) и алкилированный поперечносшитый полимер для осуществления способа (варианты) | |
US7608674B2 (en) | Pharmaceutical compositions comprising cross-linked small molecule amine polymers | |
DK1807057T3 (en) | ALIFATIC AMINE POLYMER SALTS FOR TABLET PREPARATION | |
CZ43995A3 (en) | Cross-linked polymeric ammonium salt, its use in the preparation of a medicament and a pharmaceutical composition containing such salt | |
US20080112918A1 (en) | Method for treating gout and binding uric acid | |
US20060177415A1 (en) | Once a day formulation for phosphate binders | |
US20020187120A1 (en) | Method for treating gout and reducing serum uric acid | |
JP2004526778A (ja) | 脂肪族ポリアミンを用いるx症候群の処置方法 | |
WO1998042355A1 (en) | Phosphate-binding polymers combined with a calcium supplement for oral administration | |
CN1010550B (zh) | 制备改进的抗炎药剂的方法 | |
WO2023064357A1 (en) | Pharmaceutical compositions for the treatment of lithiasis disorders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
GD4A | Issue of patent certificate for granted invention patent | ||
MK4A | Expiration of patent term of an invention patent |